Wednesday, July 8, 2026

biotech · Major Depressive Disorder · Alzheimer's Disease · NMRA

Neumora Therapeutics

Neumora Therapeutics clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

copenhagen, DK HQ
18 Employees
Public company Type
NMRA · NYSE Ticker
Company details
Intelligence · Clinical Programs

Neumora Therapeutics projects

5 ClinicalTrials.gov programs sponsored by Neumora Therapeutics.

Neumora Therapeutics has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. NMRA-335140

    Neumora Therapeutics

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial
  2. NMRA-335140

    Neumora Therapeutics

    Major Depressive Disorder

    phase 3 small molecule active

    5 trials
  3. NMRA-335140-303

    Neumora Therapeutics

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial
  4. NMRA-335140 80 mg

    Neumora Therapeutics

    Major Depressive Episode Associated With Bipolar II Disorder

    phase 2 small molecule completed

    1 trial
  5. NMRA-323511

    Neumora Therapeutics

    Alzheimer's Disease

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Neumora Therapeutics have?

5 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.